Stryker Corporation (SYK) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Sell if holding. Momentum 3.9/10 is below the 5.0 floor at $307.80 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: sole-source suppliers; Weak growth.
Stryker is a global medical technology company with $25.1 billion in 2025 net sales across two segments: MedSurg and Neurotechnology (62%) and Orthopaedics (38%), selling surgical equipment, navigation systems, joint implants, and Mako robotic-arm technology to hospitals and... Read more
Sell if holding. Momentum 3.9/10 is below the 5.0 floor at $307.80 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: sole-source suppliers; Weak growth. Chart setup: Death cross but MACD improving, RSI 46. Score 5.2/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 45d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.
About Stryker Corporation
About Stryker Corporation
Stryker generated $25.1 billion in net sales in 2025, split between the MedSurg and Neurotechnology segment at $15.6 billion (62%) and the Orthopaedics segment at $9.5 billion (38%), with products sold in approximately 61 countries. The Mako SmartRobotics platform is deployed in more than 45 countries, and more than two million cumulative robotic procedures have been performed globally across total knee, total hip, and partial knee applications. The company employed approximately 56,000 people globally at December 31, 2025.
Stryker sells medical devices directly to hospitals and healthcare facilities, with indirect distribution channels used in markets where direct access is limited. Within MedSurg and Neurotechnology, Medical contributed $4.2 billion (27% of the segment), Endoscopy $3.8 billion (24%), Instruments $3.2 billion (20%), Neuro Cranial $2.5 billion (16%), and Vascular $2.0 billion (13%) in 2025. Within Orthopaedics, Trauma and Extremities led at $3.9 billion (42%), followed by Knees at $2.7 billion (28%) and Hips at $1.9 billion (20%). Competitors in Instruments include Zimmer Biomet, Medtronic, Johnson & Johnson MedTech, and ConMed Linvatec; in joint replacement, Stryker competes with Zimmer, Johnson & Johnson MedTech, and Smith & Nephew. Certain raw materials, components, and finished devices are procured from sole-source suppliers due to quality, intellectual property, and regulatory validation requirements, which may expose the company to product shortages if those suppliers face disruptions. Stryker acquired Inari Medical in 2025, integrating it into the Vascular business unit.
Show full overview
Stryker's products are subject to the European Union Medical Device Regulation, which imposes stricter clinical, quality, and post-market surveillance requirements with staggered compliance deadlines ranging from May 2026 through December 2028 depending on device type. China has implemented a volume-based procurement process for medical devices that has increased pricing pressure in that market. Tariffs enacted by the United States government and potential retaliatory measures by trading partners may further constrain supply chain availability. In May 2026, Stryker disclosed via Form 8-K that Vice President and Chief Accounting Officer William E. Berry Jr. will retire effective September 1, 2026, with Emily Baculik, current Corporate Controller, named as successor Chief Accounting Officer.
See also: Healthcare · Medical Devices
From Stryker Corporation's most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-06-15Recent Developments — Stryker Corporation
Material events (past 30 days)
- 8K May 20, 2026 MEDIUM Item 5.02: VP and Chief Accounting Officer William E. Berry Jr. to retire effective September 1, 2026. Emily Baculik, current VP/Corporate Controller, named as successor Chief Accounting Officer effective the same date.
Latest news
- NEWS Stryker (NYSE:SYK) Sets New 12-Month Low - Time to Sell? - MarketBeat — MarketBeat negative
- NEWS M&T Bank Corp Lowers Stake in Stryker Corporation $SYK - MarketBeat — MarketBeat neutral
- NEWS Is It Fairly Priced Now | Stryker Corporation posts 3% EPS miss vs consensus - Revenue Guidance - Cổng thông tin điện tử — Cổng thông tin điện tử tỉnh Lào Cai negative
- NEWS Universal Beteiligungs und Servicegesellschaft mbH Increases Stock Position in Stryker Corporation $SYK - MarketBeat — MarketBeat positive
- NEWS Boston Trust Walden Corp Sells 6,108 Shares of Stryker Corporation $SYK - MarketBeat — MarketBeat neutral
Generated 2026-06-17T09:12:26Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSuppliersole-source suppliers10-K Item 1A: 'several raw materials, components, finished devices and services are procured from a sole source due to, among other things, the quality considerations, unique intellectual property considerations or constraints associated with regulatory requirements'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 3.9/10 is below the 5.0 floor at $307.80 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: sole-source suppliers; Weak growth. Chart setup: Death cross but MACD improving, RSI 46. Prior stop was $291.08. Score 5.2/10, moderate confidence.
Take-profit target: $348.12 (+13.0% upside). Prior stop was $291.08. Stop-loss: $291.08.
Concentration risk — Supplier: sole-source suppliers; Weak growth; Negative momentum.
Stryker Corporation trades at a P/E of 36.1 (forward 18.7). TrendMatrix value score: 5.1/10. Verdict: Sell.
35 analysts cover SYK with a consensus score of 4.1/5. Average price target: $387.
What does Stryker Corporation do?Stryker is a global medical technology company with $25.1 billion in 2025 net sales across two segments: MedSurg and...
Stryker is a global medical technology company with $25.1 billion in 2025 net sales across two segments: MedSurg and Neurotechnology (62%) and Orthopaedics (38%), selling surgical equipment, navigation systems, joint implants, and Mako robotic-arm technology to hospitals and surgeons in approximately 61 countries. No commercial customer accounted for more than 10% of net sales in 2025.